Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus
- Registration Number
- NCT01542060
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 298
Inclusion Criteria
- Subjects from hospitals or clinics, diagnosed with type 2 diabetes mellitus
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description BIAsp 30 users biphasic insulin aspart 30 -
- Primary Outcome Measures
Name Time Method HbA1c (glycosylated haemoglobin)
- Secondary Outcome Measures
Name Time Method Incidence of adverse events Incidence of hypoglycaemic episodes FBG (Fasting Blood Glucose) Quality of life assessed through the WHO-DTSQ (World Health Organization-Diabetes Treatment Satisfaction Questionnaire)